Stockscreener 앱 받기
74.73
0.82%
0.61
전일 마감가:
$74.12
열려 있는:
$74.82
하루 거래량:
13.45M
Relative Volume:
1.04
시가총액:
$110.83B
수익:
$20.08B
순이익/손실:
$2.89B
주가수익비율:
38.54
EPS:
1.9391
순현금흐름:
$3.82B
1주 성능:
-2.02%
1개월 성능:
-20.62%
6개월 성능:
-27.09%
1년 성능:
-29.59%
1일 변동 폭
$74.43
$76.37
1주일 범위
$72.69
$76.37
52주 변동 폭
$72.69
$109.50
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-03 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-09-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-16 | 개시 | Leerink Partners | Outperform |
| 2025-04-16 | 업그레이드 | Needham | Hold → Buy |
| 2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-20 | 재개 | Citigroup | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-27 | 업그레이드 | Needham | Hold → Buy |
| 2022-04-13 | 재개 | Truist | Buy |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Buy |
| 2019-12-30 | 재확인 | Cowen | Outperform |
| 2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-09-05 | 재개 | JP Morgan | Overweight |
| 2019-09-03 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-10-02 | 재확인 | Morgan Stanley | Overweight |
| 2018-09-07 | 재확인 | Needham | Strong Buy |
| 2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-07-06 | 재확인 | Needham | Strong Buy |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference - Finviz
Boston Scientific Corp (NYSE:BSX) Emerges as a Prime GARP Candidate - ChartMill
Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference – Company Announcement - Financial Times
Public Sector Pension Investment Board Purchases 903,448 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Shares Sold by Illinois Municipal Retirement Fund - MarketBeat
Will Boston Scientific Corporation stock hit new highs in YEAR2025 Trade Ideas & Long-Term Growth Stock Strategies - mfd.ru
Is Boston Scientific Corporation still a buy after recent gainsOptions Play & Momentum Based Trading Signals - mfd.ru
Boston Sci’s Farapulse better than thermal ablation at 4 years - BioWorld MedTech
The Top 5 Analyst Questions From Boston Scientific's Q4 Earnings Call - Finviz
Impax Asset Management Group plc Boosts Holdings in Boston Scientific Corporation $BSX - MarketBeat
Aug EndMonth: Can Boston Scientific Corporation sustain its profitabilityMarket Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments - GlobeNewswire Inc.
Boston Scientific Board Change Puts Growth And Risk Oversight In Focus - Yahoo Finance
Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus - TechStock²
Boston Scientific (NYSE:BSX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Levi & Korsinsky Investigates Possible Securities Fraud by Boston Scientific Corporation (BSX) - marketscreener.com
Boston Scientific Farapulse PFA outperforms thermal ablation in study - MassDevice
Boston Scientific (BSX) Analyst Ratings and Price Targets Update - GuruFocus
Boston Scientific stock price slips again: BSX extends slide as heart-rhythm worries linger - TechStock²
Fraud Investigation Opened: Levi & Korsinsky Investigates Boston Scientific Corporation (BSX) on Behalf of Shareholders - marketscreener.com
Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback - Finviz
Why Analysts See Boston Scientific (BSX) Differently After Target Cuts And A Fair Value Reset - Yahoo Finance
Boston Scientific (NYSE:BSX) Cut to "Hold" at Wall Street Zen - MarketBeat
Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales - TechStock²
Boston Scientific’s Worst Day in 25 Years Surprised Analysts - Bloomberg.com
Boston Scientific to Report Q4 Earnings with Expected Growth - Intellectia AI
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Chartmill
Bernstein SocGen lowers Boston Scientific stock price target on EP miss - Investing.com
RBC Capital lowers Boston Scientific stock price target to $115 on 2026 guidance - Investing.com
Boston Scientific stock holds Outperform rating at Evercore despite EP miss - Investing.com
Boston Scientific price target lowered to $110 from $125 at Stifel - Yahoo Finance
Boston Scientific Corp (NYSE:BSX) Reports Strong Q2 2025 Earnings, Surpassing Revenue and EPS Estimates - Chartmill
Boston Scientific’s (BSX) Earnings Implosion Sparks Bullish Options Trade - TipRanks
Boston Scientific (BSX): Analyst Ratings Update and Target Price Changes | BSX Stock News - GuruFocus
Boston Scientific (BSX): Canaccord Genuity Adjusts Price Target, Maintains Buy Rating | BSX Stock News - GuruFocus
Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries - TechStock²
The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition - FinancialContent
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Boston Scientific Corporation Announces Yoshiaki Fujimori to Not Stand for Re-Election as Director - marketscreener.com
Boston Scientific announces planned board director departure - TipRanks
JPMorgan Chase & Co. Issues Pessimistic Forecast for Boston Scientific (NYSE:BSX) Stock Price - MarketBeat
Boston Scientific Announces Board Member Departure - TradingView
JP Morgan Maintains "Overweight" on Boston Scientific (BSX) but Lowers Price Target | BSX Stock News - GuruFocus
Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next - TechStock²
What Happened To Boston Scientific Stock? - Forbes
Investors in Boston Scientific Corporation (BSX) Warned of Potential Securities FraudContact Levi & Korsinsky Today - marketscreener.com
Wells Fargo & Company Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price - MarketBeat
Deutsche Bank Adjusts Boston Scientific PT to $90 From $129, Maintains Buy Rating - marketscreener.com
Boston Scientific Share Performance Hinges on CHAMPION-AF Clinical Trial Results, RBC Says - marketscreener.com
Is Boston Scientific’s Bull Thesis Still Intact? - Trefis
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.05%
자본화:
|
볼륨(24시간):